Avantor introduced a new sterile sampling suite that includes pre‑engineered PUPSIT assemblies and a modular sampling platform, designed to simplify qualification steps, reduce contamination risk, and support faster in‑process decisions for bioprocessing customers.
The suite, comprising NBSS, NFSS, EVSS, and OmniTop systems, features closed‑path designs, standardized bills of materials, and documentation that streamline setup and qualification. Supplier‑agnostic components and common filtration trains allow manufacturers to standardize across sites and scales while minimizing line breaks and operator intervention.
The launch strengthens Avantor’s position in a high‑growth bioprocessing segment that is central to its long‑term strategy. The new products address common pain points for biopharma manufacturers, potentially driving incremental revenue and reinforcing customer loyalty in the Laboratory Solutions and Bioscience Production segments.
Avantor reported Q3 2025 net sales of $1.5 billion, a 5.3% year‑over‑year decline, and a net loss of $711.8 million largely due to a $785 million goodwill impairment. Adjusted EPS was $0.22. Laboratory Solutions net sales fell 6.4%, while Bioscience Production net sales fell 2.9%. The company lowered its full‑year guidance for organic revenue growth and adjusted EPS but announced a $500 million share repurchase program.
Management highlighted that the new suite addresses contamination risk and qualification challenges faced by biopharma manufacturers and is part of a broader effort to deliver mission‑critical solutions for life‑sciences and advanced‑technology customers.
The company expects the new suite to contribute to incremental revenue in the Bioscience Production segment, which saw a 2.9% decline in Q3 2025, and to support the segment’s recovery in the coming quarters.
Avantor has a history of launching bioprocessing and sampling solutions, including the OmniTop Sample Tubes Adjustable Volume Sampling System in 2022. The new sterile sampling suite expands and enhances the company’s existing product portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.